ClinicalTrials.gg
CompletedNCT05023486Updated Oct 9, 2026

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

A Phase 1/2 interventional study of NP-G2-044 Monotherapy and Anti-PD-1 Therapy in Advanced or Metastatic Solid Tumor Malignancies, sponsored by Novita Pharmaceuticals, Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Novita Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

Updated Oct 9, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
121
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.

02

Conditions studied

  • Advanced or Metastatic Solid Tumor Malignancies

Keywords

  • Advanced or Metastatic Solid Tumor Malignancies
03

In context

Lead sponsor

Novita Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Male or female ≥18 years of age;
  2. (ECOG) Performance Status of 0 or 1;
  3. of > 6 months;
  4. Abilty to swallow capsules and tablets;
  5. Adequate organ and bone marrow function, defined by the following:

    >1500 cells/μL; >9.0 g/dL; count >100,000 cells/μL; Total ≤1.5 mg/dL; Albumin ≥3.0 g/dL; , aspartate aminotransferase, alkaline phosphatase, and gamma-glutamyl transferase ≤2.5 × (ULN); ≥50 mL/min; and and partial thromboplastin time ≤1.5 × ULN.

  6. Female patients of must have a negative serum or urine pregnancy test at Screening and within 24 hours (if urine test) or 72 hours (if serum test) before the first dose of NP-G2-044. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required and must be negative for the patient to be eligible; Note: A woman is considered to be childbearing potential unless she is (≥1 year without menses and confirmed with a follicle-stimulating hormone [FSH] test) or surgically sterilized via bilateral oophorectomy, hysterectomy, bilateral tubal ligation, or successful Essure® placement with a documented confirmation test at least 3 months after the procedure.
  7. Male patients must be surgically sterile or willing to use a highly effective double-barrier method (e.g., male condom with diaphragm or male condom with cervical cap) upon study entry, while on NP-G2-044, and for a period of at least 4 months following the last dose of NP-G2-044; and
  8. Able to understand and voluntarily sign a written form (ICF) and willing and able to comply with protocol requirements.

Inclusion Criteria for NP-G2-044 Monotherapy:

Patients must meet all the following criteria to receive NP-G2-044 monotherapy in the study:

  1. Have a histopathologically confirmed advanced or solid tumor for which standard therapies are no longer effective, not tolerated or ineligible for the patient to receive;
  2. Have per version 1.1 (RECIST 1.1);
  3. For monotherapy expansion cohort A (after the Mono-RP2D has been identified), patients must have:

    1. Gynecologic malignancies including ovarian, endometrial/uterine, fallopian tube, cervical, vulvar, and vaginal cancers; or
    2. Epidermal growth factor receptor (EGFR)-high (2+ or 3+ staining per DAKO criteria or genomic sequencing data showing 3 or more copies of the EGFR gene) triple-negative breast cancer (TNBC).
  4. For Monotherapy Expansion Cohort B, patient must have advanced or metastatic solid tumors malignancy

Inclusion Criteria for NP-G2-044 Combination Therapy Patients must meet the following criteria to receive NP-G2-044 in combination with therapy in the study:

  1. Have measurable disease per RECIST 1.1;

    For Combination Therapy Expansion Cohort A:

  2. Patients must meet 1 of the following criteria to enroll in Combination Therapy Expansion Cohort A:

    1. Have initiated anti-PD-(L)1 therapy in accordance with the package insert and have been receiving the anti-PD-(L)1 therapy for ≥3 months (with therapy currently ongoing) and have stable disease (defined either by post-treatment onset radiographic scan or ≥3 months without radiographic or clinical evidence of progression), or had an initial period of stable disease and now have an initial scan demonstrating progressive disease per RECIST 1.1. or
    2. Have discontinued prior anti-PD-(L)1 therapy and are now eligible for de novo NP-G2-044 plus standard of care anti-PD-1 therapy.

    For Combination Therapy Expansion Cohorts B through E:

  3. Patients must meet 1 of the following criteria to enroll in Combination Therapy Expansion Cohorts B through E:

    1. Have initiated anti-PD-(L)1 therapy. in accordance with the package insert and have been receiving the anti-PD-(L)1 therapy for >3 months (with therapy currently ongoing) and have stable disease (as defined above), or had an initial period of stable disease or response and now have an initial scan demonstrating progressive disease per RECIST 1.1; or
    2. Have confirmed progressive disease and discontinued prior anti-PD-(L)1 therapy and are now eligible for de novo NP-G2-044 plus standard of care anti-PD-1 therapy.
  4. For Combination Therapy Expansion Cohort B, patients must have cutaneous squamous cell carcinoma (CSCC) (human papilloma virus [HPV]-positive or -negative; documentation of HPV status is required);
  5. For Combination Therapy Expansion Cohort C, patients must have either:

    1. Esophageal squamous cell carcinoma (ESCC) (HPV-positive or -negative; documentation of HPV status is required); or
    2. Oropharyngeal squamous cell carcinoma (OPSCC) (HPV-positive or -negative; documentation of HPV status is required).
  6. For Combination Therapy Expansion Cohort D, patients must have non muscle invasive bladder cancer (NMIBC) meeting Bacillus Calmette-Guérin (BCG)-unresponsive criteria;
  7. For Combination Therapy Expansion Cohort E, patients must have microsatellite instability high (MSI-H) cancer;

    For Combination Therapy Expansion Cohorts F and G:

  8. For Combination Therapy Expansion Cohort F, patients must be immunotherapy naïve (I O naïve), have pancreatic ductal adenocarcinoma (PDAC), and meet the following criteria:

    1. Have had stable disease or response with at least 4 months of standard of care chemotherapy;
    2. Have no liver metastasis; and
    3. Have albumin within the normal range at Screening and >3.5 g/dL (±10%) 3 days before Cycle 1 Day 1.
  9. For Combination Therapy Expansion Cohort G, patients must be I O naïve, have platinum resistant ovarian cancer (PROC), and meet the following criteria:

    1. Had disease recurrence during or within 6 months after last administration of platinum-based chemotherapy; and
    2. Received no more than 2 prior regimens of systemic therapy after development of platinum resistance.

Exclusion Criteria:

  1. Received chemotherapy or radiotherapy within 4 weeks or 5 half-lives, whichever is shorter, of the first dose of NP-G2-044; Note: Prior immunotherapy is allowed for patients receiving NP-G2-044 monotherapy. For PDAC patients in Combination Therapy Expansion Cohort F: received systemic therapy within 2 weeks of the first dose of NP-G2-044.
  2. Unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than v5.0 Grade ≤2 alopecia or neuropathy) not yet resolved to NCI CTCAE v5.0 Grade ≤1; Note: Patients who experienced a Grade ≥3 anti-PD-1-related AE per NCI CTCAE v5.0 are excluded unless recovered and approved by the Novita Medical Monitor or designee.
  3. Receiving any other agent(s) or have received an investigational agent within 4 weeks of the first dose of NP-G2-044; Note: Patients who have progressed on NP-G2-044 treatment prior to this study are not eligible
  4. Known untreated or treated brain metastases that have not been radiographically and clinically stable (i.e., not requiring ) ≥4 weeks prior to study enrollment;
  5. by Fridericia method >470 msec or (ECG) with evidence of conduction abnormalities or active ischemia as determined by the Investigator;
  6. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or inflammatory diseases, or psychiatric illness/social situations that would limit compliance with study requirements;
  7. Pregnant, lactating, or is planning to attempt to become pregnant or impregnate someone during the study or within 90 days after dosing of NP-G2-044;
  8. Received prior allogenic hematopoietic stem cell transplantation or allogenic bone marrow transplantation;
  9. Received prior solid organ transplantation;
  10. Ongoing therapy (≥10 mg/day of prednisone or its equivalent);
  11. Requires the use of a strong inhibitor or inducer of cytochrome P450 (CYP)3A4, CYP1A2, or CYP2D6 during the study;
  12. History of clinically meaningful gastrointestinal bleeding, intestinal obstruction, or gastrointestinal perforation within 6 months of study enrollment;
  13. Excluded by the Sponsor due to medical history, physical examination findings, clinical laboratory results, prior medications, or other entrance criteria; or
  14. For PDAC patients in Combination Therapy Expansion Cohort F only: have a documented rise in tumor markers within the last 4 months.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    NP-G2-044 Monotherapy - Capsule/Tablet

    NP-G2-044 capsule/tablet PO QD for each 28-day cycle

    Drug: NP-G2-044 Monotherapy

  • Experimental
    NP-G2-044 Combination Therapy With Anti-PD-1 Therapy

    NP-G2-044 capsules PO QD for each 28-day cycle, Anti-PD-1 Therapy per standard of care, at a dose and frequency in accordance with the package insert

    Drug: Anti-PD-1 Therapy · Drug: NP-G2-044 Combination therapy

Interventions

  • 1600 mg QD, 2000mg QD, and 2100 mg QD

  • DrugAnti-PD-1 Therapy

    previously initiated per standard of care, at a dose and frequency in accordance with the package insert

  • DrugNP-G2-044 Combination therapy

    Drug page: NP-G2-044

    1600 mg QD or 2100 mg QD

06

What researchers measure

Primary outcomes

  1. Identification of the NP-G2-044 Monotherapy Recommended Phase 2 Dose (RP2D)

    Time frame: 6 months

  2. Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 monotherapy

    Will use NCI CTCAE v5.0

    Time frame: Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)

  3. NP-G2-044 anti-tumor preliminary efficacy signals when administered as continuously dosed monotherapy assessed by RECIST 1.1

    (computed tomography \[CT\] or magnetic resonance imaging \[MRI\])

    Time frame: 24 months

  4. Identification of the RP2D for patients receiving NP-G2-044 in combination with anti-PD-1 therapy

    Time frame: 9 months

  5. Number of incidences of Treatment Emergent Adverse Events with NP-G2-044 and anti-PD-1 combination therapy

    Will use NCI CTCAE v5.0

    Time frame: Time of first dose of any study drug(s) until 30 days after the last dose of study drug(s)

  6. NP-G2-044 anti-tumor preliminary efficacy signals when administered in combination with anti-PD-1 therapy assessed by RECIST 1.1

    (computed tomography \[CT\] or magnetic resonance imaging \[MRI\])

    Time frame: 24 months

Secondary outcomes

  1. Identify and characterize preliminary anti-tumor activity of NP-G2-044 in combination with anti-PD-1 therapy

    Anti-tumor activity assessed using iRECIST

    Time frame: 24 months

  2. Pharmacokinetics (PK) of NP-G2-044 monotherapy: AUC

    Area under the plasma concentration versus time curve

    Time frame: 6 months

  3. Pharmacokinetics (PK) of NP-G2-044 monotherapy: Tmax

    Time to peak plasma concentration

    Time frame: 6 months

  4. Pharmacokinetics (PK) of NP-G2-044 monotherapy: Cmax

    Peak plasma concentration

    Time frame: 6 months

  5. Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: AUC

    Area under the plasma concentration versus time curve

    Time frame: 9 months

  6. Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: Tmax

    Time to peak plasma concentration

    Time frame: 9 months

  7. Pharmacokinetics (PK) of NP-G2-044 and anti-PD-1 Combination therapy: Cmax

    Peak plasma concentration

    Time frame: 9 months

07

Study locations

18 sites
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
  • University of Arizona - Cancer Center
    Tucson, Arizona 85719, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • City of Hope
    Duarte, California 91010, United States
  • City of Hope Irvine Lennar
    Irvine, California 92618, United States
  • Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates
    Newport Beach, California 92663, United States
  • Nuvance Health
    Norwalk, Connecticut 06856, United States
  • University of Florida (UF) - Shands Cancer Center
    Gainesville, Florida 32610, United States
  • Indiana University (IU) Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Cancer Center
    Fairway, Kansas 66205, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Atlantic Health System - Morristown Medical Center
    Morristown, New Jersey 07962, United States
  • University of Cincinnati (UC) - Cancer Institute
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Virginia Commonwealth University - Massey Cancer Center
    Richmond, Virginia 23298, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2026, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2021
First posted
Aug 26, 2021
StartActual
Dec 7, 2021
Primary completionActual
Jun 30, 2026
CompletionActual
Jun 30, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05023486
Lead sponsor
Novita Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Dec 7, 2021
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026
Last update
Oct 9, 2026

Study contacts

Jillian Zhang, Ph.D.
study director · Novita Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NP-G2-044

Start the discussion